Our lab operates at the interface between basic research and clinical research also known as cancer translational research. We specifically focus on breast cancer translational research. At the core of our laboratory is the constant dialog between clinicians and scientists. The process of translational research can be viewed as a cycle with defined phases and identifiable checkpoints showing how novel findings can be readily translated into clinical trials. Fundamental clinical observations lead to new directions of research and from the original hypothesis, through early scientific testing and preclinical tests the discovery ultimately moves into the clinic. This integrated approach has the potential to bring personalized medicine to the forefront of patient care. We use multiple approaches to decipher the mechanisms involved in breast cancer progression and resistance development to anti-cancer drugs. Moreover, we operate to contribute to the development of personalized medicine that tailors medical treatments to individual patients. An important goal for the lab is the generation of a very powerful translational research tool- a living- biobank of breast cancer organoids. Via assembly of a collection of breast cancer tumor tissues we will pursue the identification of genomic, proteomic and metabolic signatures for individualized therapies. Our lab benefits from a direct access to clinical databases and to biological samples, including a tissue-bank, facilitating relevant and significant translational research. The laboratory also benefits from both, the strong clinical platform of the Breast Cancer Division and the cutting edge technological and scientific facilities available at the medical center. The Laboratory operates to establish close collaborations between basic research scientists, bioinformaticians, oncologists, radiologists and pathologists from Israel and from worldwide leading academic and medical institutes.